Moderna to build Covid-19 vaccine facility in Canada: PM Justin Trudeau

Construction is set to start this year and the facility is expected to be operational in 2024 at the earliest, subject to planning and regulatory approvals, Trudeau said on Friday in a press release

Moderna Covid-19 vaccine
Moderna is applying for a vaccine to protect children between six months and five-years-old in Canada
IANS Ottawa
2 min read Last Updated : Apr 30 2022 | 10:21 AM IST

Canadian Prime Minister Justin Trudeau has announced that Covid-19 vaccine developer Moderna will build a manufacturing facility in the country's Quebec to deliver up to 100 million mRNA vaccine doses annually.

Construction is set to start this year and the facility is expected to be operational in 2024 at the earliest, subject to planning and regulatory approvals, Trudeau said on Friday in a press release.

In addition to Covid-19 vaccines, the facility is expected to be able to produce vaccines for other respiratory diseases such as influenza, pending the ongoing development by Moderna and approval by Health Canada, according to the news release.

"Covid-19 vaccines saved lives and got Canadians back to doing the things they love," the Prime Minister added.

Canadian Health Minister, Jean-Yves Duclos said the government will build a domestic biomanufacturing capacity to ensure that Canada continues to have access to vaccines well into the future, Xinhua news agency reported.

Health Canada authorised Moderna's Spikevax vaccine for adults in December 2020, teenagers in August 2021 and for children aged between six to 11 years in March 2022. More than 29 million doses of Spikevax vaccine have been distributed across Canada.

The company is applying for a vaccine to protect children between six months and five-years-old in Canada. Currently there is no vaccine authorised for children younger than five years.

--IANS

int/khz/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccinePM Justin TrudeauCanada

First Published: Apr 30 2022 | 10:21 AM IST

Next Story